<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794455</url>
  </required_header>
  <id_info>
    <org_study_id>VR5642</org_study_id>
    <nct_id>NCT01794455</nct_id>
  </id_info>
  <brief_title>Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression</brief_title>
  <official_title>Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot proposal will test the hypothesis that altered cerebral vessel reactivity and
      cerebral hypoperfusion (decreased blood flow to the brain) is a core mechanism underlying the
      relationship between vascular disease and depression in older adults. The long-term objective
      of this line of research is to: A) determine the relationship between vascular reactivity,
      cerebral hypoperfusion and the persistence of late-life depression and B) determine if
      improving cerebral perfusion with angiotensin receptor blockers (ARBs) improves depression
      outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine how magnetic resonance imaging (MRI) measures of cerebral perfusion
      relate to antidepressant response. There are two phases to the study. In the first phase, we
      will examine how cerebral perfusion is related to response to sertraline, a commonly used
      antidepressant. In the second phase, we will examine individuals who do not respond to
      sertraline or other selective serotonin reuptake inhibitors (SSRI). We will examine if
      candesartan, an ARB, improves depression and if it does so by improving cerebral perfusion.

      After providing informed consent, participants will undergo medical and psychiatric
      screening. Participants determined to be eligible at the screen will proceed to a baseline
      evaluation, which will include brief cognitive neuropsychological testing and MRI.
      Participants will then begin open-label sertraline for eight weeks (baseline to week 8).
      Dosing will begin at 50mg daily and, based on response and tolerability, can increase up to
      the FDA approved maximum dose of 200mg daily.

      After the eight weeks, participants will be re-evaluated and complete another MRI. Those who
      respond to sertraline and experience remission of their depression will end their study
      participation. Those who do not experience remission will continue to the phase 2 open-label
      candesartan arm.

      The candesartan arm will last for 12 weeks (week 8 to week 20). Dosing will begin at 4mg
      daily and can increase to a maximum dose of 32mg, based on tolerability and response.
      Participants will be monitored closely, and other antihypertensive medications adjusted to
      avoid low blood pressure. At the end of the 12-week trial, participants will again complete
      MRI and neuropsychological testing. Their study participation will then end.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment difficulties
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI Arterial Spin Labeling</measure>
    <time_frame>Change in perfusion from baseline to week 8</time_frame>
    <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 1 sertraline arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Week 8</time_frame>
    <description>MADRS is a measure of depression severity. This outcome applies to the sertraline Phase 1 arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</measure>
    <time_frame>Week 8</time_frame>
    <description>Self-report measure of depression severity. This applies to the sertraline Phase 1 arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</measure>
    <time_frame>Week 20</time_frame>
    <description>Self-report measure of depression severity (range 0 - 27, higher scores indicate more severe depressive symptoms). This applies to the candesartan Phase 2 arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale</measure>
    <time_frame>Week 20</time_frame>
    <description>MADRS is a measure of depression severity (range 0 - 60, higher scores indicate more severe depressive symptoms). This outcome applies to the candesartan Phase 2 arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Arterial Spin Labeling</measure>
    <time_frame>Change from week 8 to week 20</time_frame>
    <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 2 candesartan arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Depression</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Phase 1: Sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Candesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>50mg - 200mg daily</description>
    <arm_group_label>Phase 1: Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>4mg - 32mg daily</description>
    <arm_group_label>Phase 2: Candesartan</arm_group_label>
    <other_name>Atacand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 60 years or older

          2. Diagnosis of Major Depressive Disorder, single or recurrent episode, without psychotic
             features by Diagnostic and Statistical Manual IV Text Revision (DSMIV-TR) criteria

          3. Presence of hypertension (defined as systolic &gt; 140 or diastolic &gt; 90 or currently
             receiving antihypertensive therapy)

          4. Minimum depression severity of ≥ 15 on the Montgomery-Asberg Depression Rating Scale
             (MADRS)

          5. Cognitively intact or with mild cognitive deficits, with a minimum score ≥ 23 on the
             Montreal Cognitive Assessment (MoCA).

        Exclusion Criteria:

          1. Other psychiatric Axis I disorders

          2. Acute suicidality

          3. Electroconvulsive therapy in the last 6 months

          4. Primary neurological disorder, including dementia and stroke

          5. Significant cardiovascular disease, specifically diagnosis of congestive heart
             failure, known bilateral renal artery stenosis, symptomatic hypotension, or critical
             aortic or mitral stenosis

          6. Myocardial infarction or open-heart surgery in last 6 weeks

          7. Serum creatinine ≥ 265 micromol /L

          8. Serum potassium ≥ 5.5 mmol/L

          9. MRI contraindications

         10. Known allergy to sertraline or candesartan specifically or known allergy to other
             SSRIs or ARBs.

         11. History of prolonged (&gt; 3 weeks) or self-described severe discontinuation syndrome in
             the past after stopping an antidepressant.

         12. Current use of an angiotensin receptor blocker

         13. Current or planned psychotherapy

         14. Need for continuous oxygen use or any medical disorder where the hypercapnia challenge
             would be contraindicated or put the subject at increased risk. This would include
             acute respiratory disease, chronic angina, or other unstable cardiac conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren D Taylor, MD, MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Psychiatric Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <results_first_submitted>July 18, 2016</results_first_submitted>
  <results_first_submitted_qc>August 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2016</results_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Warren Taylor</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Depressive Disorder</keyword>
  <keyword>Geriatrics</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase 1: Sertraline</title>
          <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
Sertraline: 50mg - 200mg daily</description>
        </group>
        <group group_id="P2">
          <title>Phase 2: Candesartan</title>
          <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
Candesartan: 4mg - 32mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 1: Sertraline</title>
          <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
Sertraline: 50mg - 200mg daily</description>
        </group>
        <group group_id="B2">
          <title>Phase 2: Candesartan</title>
          <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
Candesartan: 4mg - 32mg daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="67" lower_limit="67" upper_limit="67"/>
                    <measurement group_id="B3" value="67" lower_limit="67" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MRI Arterial Spin Labeling</title>
        <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 1 sertraline arm.</description>
        <time_frame>Change in perfusion from baseline to week 8</time_frame>
        <population>Could not complete MRI.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Arterial Spin Labeling</title>
          <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 1 sertraline arm.</description>
          <population>Could not complete MRI.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
        <description>MADRS is a measure of depression severity. This outcome applies to the sertraline Phase 1 arm.</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS)</title>
          <description>MADRS is a measure of depression severity. This outcome applies to the sertraline Phase 1 arm.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</title>
        <description>Self-report measure of depression severity. This applies to the sertraline Phase 1 arm.</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</title>
          <description>Self-report measure of depression severity. This applies to the sertraline Phase 1 arm.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</title>
        <description>Self-report measure of depression severity (range 0 - 27, higher scores indicate more severe depressive symptoms). This applies to the candesartan Phase 2 arm.</description>
        <time_frame>Week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)</title>
          <description>Self-report measure of depression severity (range 0 - 27, higher scores indicate more severe depressive symptoms). This applies to the candesartan Phase 2 arm.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery-Asberg Depression Rating Scale</title>
        <description>MADRS is a measure of depression severity (range 0 - 60, higher scores indicate more severe depressive symptoms). This outcome applies to the candesartan Phase 2 arm.</description>
        <time_frame>Week 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale</title>
          <description>MADRS is a measure of depression severity (range 0 - 60, higher scores indicate more severe depressive symptoms). This outcome applies to the candesartan Phase 2 arm.</description>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRI Arterial Spin Labeling</title>
        <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 2 candesartan arm.</description>
        <time_frame>Change from week 8 to week 20</time_frame>
        <population>MRI data could not be obtained on the one study participant due to MRI contraindications.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Sertraline</title>
            <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
Sertraline: 50mg - 200mg daily</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: Candesartan</title>
            <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
Candesartan: 4mg - 32mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Arterial Spin Labeling</title>
          <description>MRI arterial spin labeling is a noninvasive approach to measuring cerebral blood flow. This relates to the Phase 2 candesartan arm.</description>
          <population>MRI data could not be obtained on the one study participant due to MRI contraindications.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase 1: Sertraline</title>
          <description>Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
Sertraline: 50mg - 200mg daily</description>
        </group>
        <group group_id="E2">
          <title>Phase 2: Candesartan</title>
          <description>For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
Candesartan: 4mg - 32mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was ended early due to difficulty with subject recruitment. MRI data could not be obtained on that one individual due to MRI contraindications.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Warren Taylor</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-936-3555</phone>
      <email>warren.d.taylor@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

